Open AccessHeterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation
Author(s) -
Xu ChongRui,
Zhong WenZhao,
Zhou Qing,
Zhang XuChao,
Yang JinJi,
Wu YiLong
Publication year - 2017
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12382
Subject(s) - gefitinib , t790m , medicine , epidermal growth factor receptor , lung cancer , oncology , cancer research , epidermal growth factor , lung , chemotherapy , biopsy , mutation , pathology , cancer , receptor , biology , gene , biochemistry
We report the case of a 37‐year‐old male non‐small cell lung cancer patient with an active epidermal growth factor receptor ( EGFR) mutation who received gefitinib as first‐line treatment. After 13.7 months, the patient experienced disease progression and was treated with platinum‐based doublet chemotherapy plus gefitinib for 5.4 months. A subsequent lung biopsy showed cMET overexpression; therefore, the patient received a cMET inhibitor with the gefitinib. The response in the different lesions of several organs was diverse. Stable disease was achieved in the lung lesion; however, the liver metastases enlarged. A liver biopsy found T 790 M mutation in EGFR exon 20, thus, third generation EGFR‐ tyrosine kinase inhibitors were used and a partial response was achieved.